Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics appointed Dr. Will Charlton as Chief Medical Officer, effective immediately, to strengthen its clinical leadership team. Dr. Charlton brings nearly two decades of experience in rare disease and pediatric drug development, having previously led clinical programs at Tyra Biosciences and served as CMO at Spruce Biosciences.
Key figures
- Drug Name
- PLX-200
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.